Work Packages
The objectives of the STEPUPIORS project will be reached through
5 Working Packages (WPs)which would interrelate during the proposed 36-month period.
WP1 is focused on improving the existing infrastructure at IORS and building human capacities along with the establishment of a rectal cancer biobank. Biospecimens from rectal cancer patients would be processed, organized, and maintained following standard operating procedures (SOPs) related to biobanks. In collaboration with partner institutions, IORS personnel will be trained in a range of biobank-related procedures and protocols to ensure high quality of biobanking.
WP2 is focused on determining the molecular profile associated with response to CRT in LARC patients. In silico methods as well as wet-lab analyses from tissue and liquid biopsy will be used for uncovering prognostic markers in this setting.
WP3 is directed on establishing short- and long-term knowledge exchange in the rectal cancer consortium based on organization of workshops and summer schools, staff exchanges and mentoring. Visits will focus on presentation of omics approaches and their integration with clinical data, preparation of proposals for EU funding calls, and clinical application of liquid biopsies. The exchange of experiences of administrative staff will facilitate the establishment of a research management office at IORS.
WP4 is dedicated to dissemination of achieved research data, managed in line with the FAIR data principles of Findability, Accessibility, Interoperability and Reusability, through open-access publications, as well as during the presentations in international and national meetings. The STEPUPIORS project will communicate to the general public, university students, patients’ organizations during various outreach activities.
WP5 is aimed at establishing a Research Management Office (RMO) at IORS that will support the management of this and future EU-funded projects. The RMO will consist of a team of scientists and administrators that will support and coordinate services in all phases of the project.
WP1 is focused on improving the existing infrastructure at IORS and building human capacities along with the establishment of a rectal cancer biobank. Biospecimens from rectal cancer patients would be processed, organized, and maintained following standard operating procedures (SOPs) related to biobanks. In collaboration with partner institutions, IORS personnel will be trained in a range of biobank-related procedures and protocols to ensure high quality of biobanking.
WP2 is focused on determining the molecular profile associated with response to CRT in LARC patients. In silico methods as well as wet-lab analyses from tissue and liquid biopsy will be used for uncovering prognostic markers in this setting.
WP3 is directed on establishing short- and long-term knowledge exchange in the rectal cancer consortium based on organization of workshops and summer schools, staff exchanges and mentoring. Visits will focus on presentation of omics approaches and their integration with clinical data, preparation of proposals for EU funding calls, and clinical application of liquid biopsies. The exchange of experiences of administrative staff will facilitate the establishment of a research management office at IORS.
WP4 is dedicated to dissemination of achieved research data, managed in line with the FAIR data principles of Findability, Accessibility, Interoperability and Reusability, through open-access publications, as well as during the presentations in international and national meetings. The STEPUPIORS project will communicate to the general public, university students, patients’ organizations during various outreach activities.
WP5 is aimed at establishing a Research Management Office (RMO) at IORS that will support the management of this and future EU-funded projects. The RMO will consist of a team of scientists and administrators that will support and coordinate services in all phases of the project.
Project aim: establish a European consortium of research institutions dedicated to addressing an unmet clinical need of uncovering prognostic biomarkers in rectal cancer
